Impaired fasting glucose
ICD-10 R73.01 is a billable code used to indicate a diagnosis of impaired fasting glucose.
Impaired fasting glucose (IFG) is a metabolic condition characterized by elevated blood glucose levels after an overnight fast, specifically defined as a fasting plasma glucose level of 100 to 125 mg/dL (5.6 to 6.9 mmol/L). This condition is often a precursor to type 2 diabetes and is associated with insulin resistance. Patients with IFG may not exhibit overt symptoms; however, they may experience signs of metabolic syndrome, such as obesity, hypertension, and dyslipidemia. Laboratory findings typically include abnormal glucose tolerance tests and elevated HbA1c levels. IFG is significant as it indicates an increased risk for developing diabetes and cardiovascular diseases. Regular monitoring and lifestyle modifications, including diet and exercise, are crucial for managing this condition and preventing progression to diabetes.
Detailed patient history, fasting status, and lab results must be documented.
Routine screening for diabetes in at-risk populations, management of metabolic syndrome.
Consider documenting lifestyle factors and comorbidities that may influence glucose levels.
Acute care documentation should include glucose levels and any immediate interventions.
Patients presenting with symptoms of hyperglycemia or metabolic derangements.
Ensure clarity on whether the glucose measurement was taken in a fasting state.
Used when performing a fasting glucose test.
Document the fasting status and reason for testing.
Ensure that the test is ordered based on clinical guidelines.
Impaired fasting glucose indicates an increased risk for developing type 2 diabetes and cardiovascular diseases, necessitating lifestyle changes and monitoring.
